Overview
Patients with cancer have a higher incidence of AF but despite the higher incidence of AF in the cancer population, there are no randomized controlled trials (RCTs) for AF screening in this population. RCTs of AF screening in the general population have shown that screening can effectively detect AF earlier, and helps to identify candidates for appropriate anticoagulation that may lead to improvement in clinical outcomes.
Description
The Investigators will conduct an open label, prospective, pilot RCT. After informed consent, patients will be randomized 1:1 into screening or usual care. Screening will be done at a single time point. Patients randomized to screening will undergo a 30-second ECG using the Kardia Mobile device (AliveCor Inc, Cupertino, CA) paired with an iPad (Apple, Cupertino, CA). Patients randomized to usual care will not receive a screening ECG. Primary outcome will be detection of newly diagnosed AF by screening vs usual care.
Eligibility
Inclusion Criteria:
- Male and female patients age ≥65 with a current diagnosis or history of cancer.
- Patients currently undergoing or history of chemotherapy, radiotherapy or cancer related surgeries will be included.
- The age is restricted to ≥65 years because prevalence of AF is extremely low. .
Exclusion Criteria:
- Known history of atrial fibrillation.
- Non-English-speaking participants will not be enrolled